Abstract
Pneumocystis carinii pneumonia has been recognized in about 60 percent of patients with the acquired immune deficiency syndrome (AIDS). The Centers for Disease Control, in collaboration with 19 medical centers, retrospectively studied 282 biopsy-confirmed cases of P. carinii pneumonia to determine the efficacy and safety of anti-Pneumocystis therapy. Adult patients with P. carinii pneumonia secondary to AIDS and to other known causes of immune deficiency were enrolled. AIDS patients experienced a longer time from onset to diagnosis. All patients received the Standard treatments for their infections. There was no difference in survival rates through 90 days of follow-up between AIDS patients and adults with known causes of immune deficiency. However, AIDS patients required a longer duration of therapy and experienced a higher rate of relapse. Failure of therapy with trimethoprim/sulfamethoxazole was found to be a poor prognostic sign. After failure of trimethoprim/sulfamethoxazole, measures of patient outcome were similarly affected by adding or substituting pentamidine isethionate.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
